Early clinical trials for the treatment of melanoma patients describe the pulsing of in-vitro-generated DCs with either a cocktail of melanoma-associated peptides (tyrosinase, Melan-A/MART-1, gp100) or peptides derived from MAGE-1 and MAGE-3 [57]. This evidence concerns the gene MAGEA3 and melanoma.